한국형 우울장애 약물치료 알고리듬 2006 (Ⅰ) = Korean Medication Algorithm for Depressive Disorder 2006 (Ⅰ)

다국어 초록 (Multilingual Abstract)

Objectives : Since the publication of Korean Medication Algorithm Project for Major depressive Disorder (KMAP-MD) in 2002, there has been a substantial need for a revision due to rapid progress in the pharmacological management for depressive disorder. We revised KMAP-MD to Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) in 2006. This paper is one of the following 4 papers consisting of Korean pharmacological algorithm for depressive disorder.
Methods : The questionnaire consisted of 4 parts ; initial treatment of 1) non-psychotic depressive disorder, 2) psychotic depressive disorder, 3) treatment strategy for clinical subtypes and drug choice considering adverse effects, and 4) treatment for depressive disorder in women. It was composed of 22 questions, and each question had 54 sub-items. The questionnaire was completed by the review committee consisting of 101 experienced Korean psychiatrists. We classified the expert opinion to 3 categories (the first-line, the second-line, or the third-line).
Results : For non-psychotic major depression, regardless ofthe severity of an episode, the antidepressant (AD) monotherapy was the optimal first-line treatment. SSRI, venlafaxine, and mirtazapine were the 1st-line AD. In case of a partial or no response to initial strategy, adding another AD was recommended. For psychotic major depression, combination of an AD and an atypical antipsychotic (AAP) was the treatment of choice. Among AAPs, quetiapine, rispendone, olanzapine were preferred. For non-responder to initial strategy, the next step was adding or changing AD before changing AAP. For women with premenstrual dysphoric syndrome or postpartum depression without psychotic features, AD monotherapty was a preferred strategy while for psychotic postpartum depression, combination of AD and AAP was recommended. Experts recommended various ADs according to adverse effect.
Conclusion : These results suggest that the medication strategies for depressive disorder are rapidly changing and reflect the recent studies and clinical experiences.

참고문헌 (Reference)

1 Trivedi MH, "Treatment-resistant depression: new therapies on the horizon" 15 : 59-70, 2003

2 Rossini D, "Transcranial magnetic stimulation in treatment-resistant depressed patients: a double- blind, placebo-controlled trial" 137 : 1-10, 2005

3 Dodd S, "To combine or not to com-bine? A literature review of antidepresant combination therapy" 89 : 1-1, 2005

4 Nut DJ, "The role of dopamine and norepinephrine in depression and antidepressant treatment" 67 : 3-8, 2006

5 Barbee JG, "The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents intreatment-resistant major depressive disorder" 65 : 975-981, 2004

6 Lee MS, "The Executive Commitee For The Korean Medication Algorithm Project For Major Depressive Disorder. The Korean Medication Al-gorithm for Major Depresive Disorder (KMA-MD ) Report of the Korean Society of Depressive and Bipolar Disorders" 10 : 186-194, 2006

7 Sachs GS, "The Ex-pert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000" (1-104) : 2000

8 Trivedi MH, "Texas Implementation of Medication Algorithms (TIMA) Guidelines for Treating Major De-pressive Disorder, revised" 2000

9 Ruhe HG, "Switching anti-depres-sants after a first selective serotonin reuptake inhibitor in major depres-sive disorder: a systematic review" 67 : 1836-1855, 2006

10 Ellis P, "Royal Australian and New Zealand Colege of Psychiatrists Clinical Practice Guidelines Team for Depresion. Australian and New Zealand clinical practice guidelines for the treatment of depre-sion" 38 : 389-407, 2004

11 Kocsis JH, "Recurrent depression: patient characteristics, clinical co-urse, and current recommendations for management" 11 : 6 -1, 2006

12 The National Institute for Clinical Excellence (NICE), "Quick refer-ence guide, Depression: management of depression in primary and secondary care" London 2004

13 APA, "Practice Guideline for the Treatment of Patients With Major Depressive Disorder Second Edition" Arlington: VA. April 2000

14 Wijkstra J, "Pharmacological treatment for psychotic depression" 19 : CD004044-, 2005

15 Parker G, "Is combination olanzapine and anti-depressant medication asociated with a more rapid response tra-jectory than antidepressant alone?" 162 : 796-798, 2005

16 Alexopoulos GS, "Expert Consensus Panel for Pharmacotherapy of Depressive Dis-orders in Older Patients. The expert consensus guideline series. Phar-macotherapy of depressive disorders in older patients" (1-86) : 2001

17 Altshuler LL, "Expert Consensus Panel for Depression in Women. The Expert Consensus Guideline Series. Treatment of depression in wo-men" (1-107) : 2001

18 Hansen RA, "Ef-ficacy and safety of second-generation antidepressants in the treat-ment of major depressive disorder" 143 : 415-426, 2005

19 Greenberg P, "Economic implications of treatment-resistant depression among employees" 22 : 363-373, 2004

20 Rojo JE, "Combined antidepressants: clinical experience" (25-31) : 36-, 2005

21 Thorpe L, "CANMAT Depres-sion Work Group. Clinical Guide lines for the Treatment of Depre-sive Disorders" 46 : 5s-90s, 2001

22 Simon JS, "Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder" 66 : 1216-1220, 2005

23 Rush AJ, "Acute and longer-term outcomes in depressed out-patients requiring one or several treatment steps: a STAR*D report" 163 : 1905-1917, 2006

24 Gardner DM, "A comparison of factors used by physicians and patients in the selection of anti-depressant agents" 58 : 34-40, 2007